Retro-inverso bradykinin opens the door of blood–brain tumor barrier for nanocarriers in glioma treatment

zuoxu xie,qing shen,cao xie,weiyue lu,chunmei peng,xiaoli wei,xue li,bingxia su,chunli gao,min liu
DOI: https://doi.org/10.1016/j.canlet.2015.08.010
IF: 9.756
2015-01-01
Cancer Letters
Abstract:•We have designed retro-inverso bradykinin, which is characterized by resistance to proteolysis and high binding activity.•Retro-inverso bradykinin induces a change in zonula occluden-1 and F-actin to open the blood–brain tumor barrier.•Retro-inverso bradykinin increased the accumulation of drug-loaded nanocarriers in the glioma but not in normal brain.•Co-administration with retro-inverso bradykinin enhanced the therapeutic efficiency of drug-loaded nanocarriers for glioma.
What problem does this paper attempt to address?